Inducible T-cell costimulator (ICOS) is a cell-surface receptor that provides costimulatory signals to T cells, helping regulate their differentiation, survival, and function after activation. Encoded by the human ICOS gene, it belongs to the CD28 family of immune receptors and binds ICOS ligand, also called ICOSL or CD275. ICOS is particularly important for T-cell help to B cells and the development of effective antibody responses. It also supports some regulatory T-cell populations, so its effects depend on the cell type and immune setting.
Discovery and molecular organization
ICOS was described in 1999 as a receptor related to CD28 but with a distinct expression pattern and biological activity. Its identification showed that T-cell costimulation involves more than the signals needed to initiate activation: additional receptors help shape an immune response as it develops.
The human ICOS gene lies on chromosome 2, near the genes encoding CD28 and CTLA-4. Its product is a transmembrane protein with an extracellular immunoglobulin-like domain, a membrane-spanning region, and a short intracellular signaling tail. ICOS forms a disulfide-linked homodimer at the cell surface.
Its binding partner, ICOS ligand, is encoded by the separate ICOSLG gene. ICOSL is expressed by B cells, dendritic cells, and other antigen-presenting cells, as well as by some nonhematopoietic cells. Unlike CD28 and CTLA-4, ICOS does not use CD80 and CD86 as its physiological ligands.
Expression and signaling
ICOS expression is generally low on resting naïve T cells and increases following activation through the T-cell receptor. It is prominent on several activated and differentiated T-cell populations, including follicular helper T cells and subsets of regulatory T cells. Its name reflects this activation-associated induction, although expression is not restricted to newly activated cells.
ICOS engagement complements, rather than replaces, recognition of an antigen by the T-cell receptor. Binding to ICOSL promotes phosphorylation of a tyrosine-containing motif in the receptor’s intracellular tail. This motif recruits phosphoinositide 3-kinase (PI3K), initiating downstream pathways that include AKT and influence cellular survival, metabolism, and differentiation.
ICOS and CD28 have overlapping but nonidentical functions. CD28 is especially important during the initial activation of naïve T cells, whereas ICOS has major roles in shaping activated T-cell responses. ICOS can enhance the production of several cytokines, but its effects vary with the surrounding signals and the T-cell population. It does not reproduce the strong promotion of interleukin-2 production characteristic of CD28 signaling.
Role in antibody responses
A central function of ICOS is supporting follicular helper T cells (Tfh cells), the specialized CD4 T cells that provide help to B cells in lymphoid follicles. ICOS signaling contributes to the development, maintenance, and positioning of these cells.
Tfh cells participate in germinal-center reactions, where activated B cells proliferate and undergo selection. Through its support of Tfh cells, ICOS contributes to:
- Class-switch recombination, which changes the antibody class produced by a B cell.
- Affinity maturation, which increases the ability of antibodies to bind their target.
- Formation of plasma cells and memory B cells, supporting sustained antibody production and later responses to antigen exposure.
These effects are mediated through coordinated cell–cell interactions and cytokines, especially interleukin-21. ICOS is therefore important for many T-cell-dependent antibody responses, rather than being a direct trigger of antibody secretion.
Immune regulation
ICOS also contributes to immune tolerance. Some regulatory T cells express high levels of ICOS, and ICOS signaling can support their survival and suppressive activity. In certain settings, these cells produce interleukin-10, a cytokine involved in limiting immune responses.
Consequently, ICOS cannot be classified simply as a receptor that increases inflammation. It can support antibody-producing and inflammatory responses while also sustaining cells that restrain immune activity. The outcome depends on which cells express ICOS and ICOSL, the tissue environment, and accompanying signals.
Human deficiency and disease research
Rare inherited loss-of-function variants affecting both copies of ICOS cause ICOS deficiency, an inborn error of immunity. Reported features include impaired antibody responses, reduced switched-memory B cells, and recurrent infections. Some affected individuals also develop immune dysregulation. These observations provide human evidence for the importance of ICOS in T-cell-dependent B-cell function.
The ICOS–ICOSL pathway is also studied in autoimmune disease and cancer. In tumors, ICOS can be expressed by both antitumor effector T cells and suppressive regulatory T cells. Expression alone therefore does not establish whether ICOS is promoting or limiting tumor immunity.
Experimental therapeutic approaches include blocking ICOS–ICOSL interactions and using antibodies designed to stimulate ICOS. Their biological effects depend on the targeted cell population and the properties of the intervention. ICOS is also measured by flow cytometry and tissue-based methods as a marker of particular activated T-cell states; it is not, by itself, a disease-specific diagnostic marker.